Key facts
- BforCure’s last known valuation is $41.8M (Mar 2022).
- It has raised $7.9M; the latest was Later Stage VC in Feb 2025.
- Notable investors include European Commission, UCEA Capital Partners, ID Solutions (France), Ministry of Higher Education, Research and Innovation.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for BforCure
- ·The full record, as it builds
Funding rounds
No funding rounds for BforCure are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About BforCure
Developer of quantitative biosensing equipment designed for health care diagnosis and industrial applications. The company's equipment specializes in the design, production, and commercialization of a real-time PCR thermal cycler and advanced kits, enabling medical professionals to protect patients and their resources from biocontamination hazards.
- Sector
- Healthcare
- HQ
- Montreuil, France
- Founded
- 2018
- Employees
- 55
- Website
- bforcure.com/
- Ownership
- Privately Held (backing)
BforCure doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in BforCure shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on BforCure in its N-PORT filings yet. We sweep new filings monthly.